Beyond Air, Inc.

NasdaqCM:XAIR Stock Report

Market Cap: US$6.7m

Beyond Air Future Growth

Future criteria checks 2/6

Beyond Air is forecast to grow earnings and revenue by 26.5% and 57.8% per annum respectively while EPS is expected to grow by 50.3% per annum.

Key information

26.5%

Earnings growth rate

50.32%

EPS growth rate

Medical Equipment earnings growth16.4%
Revenue growth rate57.8%
Future return on equityn/a
Analyst coverage

Low

Last updated02 Jul 2026

Recent future growth updates

Recent updates

Narrative Update • Jun 17

XAIR: Hospital Access Expansion And Reverse Split Plans Will Support Future Upside

Analysts have kept their Beyond Air price target broadly stable, with only a minor adjustment that reflects small tweaks to projected profit margins and future P/E assumptions rather than a change in the core outlook. What’s in the News for Beyond Air Beyond Air scheduled a Special Shareholders Meeting for June 18, 2026, to vote on a proposal that would allow the Board to carry out a reverse stock split of the company’s common stock at a ratio between 1-for-2 and 1-for-20, at any time up to one year after the meeting, subject to shareholder approval.
Narrative Update • Jun 03

XAIR: Future Hospital Access Agreement Will Support Long Term Upside Potential

Analysts now see fair value for Beyond Air at $8.00, down from $8.67, reflecting a slightly higher discount rate and marginally softer assumptions for revenue growth, profit margin, and future P/E multiples. What's in the News Beyond Air scheduled a special shareholder meeting for June 18, 2026 at 900 Stewart Avenue, Suite 301, Garden City, New York, to vote on key corporate matters.
Narrative Update • May 06

XAIR: Later FDA Decision Will Still Drive Key Future Inflection

Narrative Update Analysts have cut their price target on Beyond Air from $6 to $2, citing lower sales estimates and a longer timeline for potential FDA approval of the second generation LungFit PH system, which they still view as central to its future revenue and profitability potential. Analyst Commentary Bearish analysts have reacted to the fiscal Q3 update by cutting their price target on Beyond Air to $2 from $6, highlighting what they see as a tougher setup for both growth and valuation in the near term.
Narrative Update • Apr 21

XAIR: Later Regulatory Decision Will Still Support Long Term Upside Potential

Analysts have cut their price target on Beyond Air to $2 from $6, citing reduced sales estimates and a longer timeline for potential FDA approval of the second generation LungFit PH system as key reasons for the reset. Analyst Commentary Bullish Takeaways Bullish analysts still point to the second generation LungFit PH system as the main potential driver for higher long term revenue and margin expansion, which they see as central to justifying a higher valuation over time.
Narrative Update • Apr 07

XAIR: Later FDA Decision Will Still Unlock Key Future Inflection

Narrative Update The analyst consensus price target for Beyond Air has shifted to $2, down from $6, as analysts point to reduced near term sales assumptions and a later FDA decision timeline for the second generation LungFit PH system, while still highlighting its potential importance for future revenue growth and profitability. Analyst Commentary Recent Street research reflects a more cautious stance on Beyond Air, with bearish analysts recalibrating expectations around both timing and scale of potential revenue from the second generation LungFit PH system.
Narrative Update • Mar 24

XAIR: Extended FDA Timeline Will Still Set Up Key Future Inflection

Analysts have cut their price target for Beyond Air to $2 from $6, citing revised sales timelines, with FDA approval for the second generation LungFit PH system now expected at the end of 2026, while still viewing that potential commercialization as central to future revenue growth and profitability. Analyst Commentary Recent price target revisions highlight a clear divide between long term optimism around LungFit PH and shorter term caution around execution and timing.
Narrative Update • Mar 10

XAIR: Future Regulatory Milestone And Capital Raise Will Underpin Potential Upside

Analysts have cut their price target on Beyond Air to $2 from $6, citing updated sales estimates and a later expected FDA decision for the second generation LungFit PH system as key drivers of their revised outlook. Analyst Commentary Bearish analysts are signaling a more cautious stance on Beyond Air, with the latest research move cutting the price target to $2 from $6 and explicitly tying that change to revised expectations around the LungFit PH opportunity and timing.
Narrative Update • Feb 23

XAIR: Later FDA Decision Will Still Support Long Term Upside Potential

Analysts have cut their average price target for Beyond Air from about $12.33 to $8.67, reflecting updated expectations for slower revenue growth, a higher discount rate, and a higher future P/E multiple as they factor in revised sales estimates tied to the later FDA decision timing for the second generation LungFit PH system. Analyst Commentary Bullish Takeaways Bullish analysts still frame the second generation LungFit PH system as a central driver for Beyond Air's long term revenue profile, pointing to commercialization of this product as a potential turning point for the business once regulatory milestones are met.
Narrative Update • Feb 09

XAIR: Bullish Coverage And New Capital Raise Will Support Future Upside

Analysts now see Beyond Air's fair value holding at $6.00 per share, with a slightly higher discount rate and modestly adjusted revenue growth, profit margin, and future P/E assumptions following fresh bullish coverage that supports a constructive long term thesis on the stock. Analyst Commentary Recent coverage frames Beyond Air as a higher risk, higher reward idea, with the current fair value estimate of US$6.00 per share sitting against a backdrop of both optimism and clear caution.
Narrative Update • Jan 25

XAIR: Expanded Distribution And Fresh Capital Will Support Future Upside

Analysts have kept their fair value target for Beyond Air steady at US$6.00, while adjusting their models to reflect updated assumptions on discount rate, revenue growth, profit margin and future P/E following recent bullish Street research coverage. Analyst Commentary While the latest Street coverage has been supportive, some bearish analysts continue to flag risks that they believe are not fully captured in the current US$6.00 fair value estimate.
Narrative Update • Jan 11

XAIR: Expanded Global Distribution And Recent Financing Will Support Future Upside

Analysts have revised their price target for Beyond Air to US$6.00, reflecting updated assumptions around the discount rate, revenue growth, profit margins and future P/E multiples, which leaves the fair value estimate unchanged at US$6.00. What's in the News Beyond Air updated its earnings guidance for the fiscal year ending March 31, 2026, with revenue now guided to a range of US$8 million to US$10 million (Corporate guidance).
Narrative Update • Dec 26

XAIR: Expanded Global Distribution And New Financing Will Support Upside Potential

Analysts have modestly raised their price target on Beyond Air to reflect a slightly higher long term growth outlook and valuation multiple, while incorporating a more conservative discount rate and largely unchanged profit margin assumptions. What's in the News Signed multiple new international distribution agreements for LungFit PH across Germany, Brazil, Austria, the Netherlands and Sri Lanka, bringing total coverage to 39 countries and over three billion people (Key Developments).
Narrative Update • Dec 12

XAIR: Stronger Revenue Outlook And Financing Will Support Future Upside Potential

Analysts have raised their price target on Beyond Air to 6.00 dollars from 5.00 dollars, citing slightly stronger expected revenue growth, modestly improved profit margins, and a higher anticipated future price to earnings multiple despite a higher discount rate. What's in the News Chief Financial Officer Doug Larson has resigned to pursue another opportunity and will remain in his role until December 5, 2025.
Narrative Update • Nov 01

XAIR: Global Network Expansion Will Drive Long-Term Market Presence

Analysts have modestly maintained their price target for Beyond Air at $12.33 per share. They cite steady expectations around revenue growth and profit margins, even though there have been minor adjustments to other financial assumptions.
Narrative Update • Oct 18

Global Expansion And Next-Generation Respiratory Care Will Transform Markets

Analysts have raised their price target for Beyond Air from $11.20 to $12.33, reflecting improved revenue growth expectations and a notable increase in projected profit margins. What's in the News The global distribution network for LungFit PH has been expanded, with new agreements in Japan, South Korea, Costa Rica, Guatemala, and El Salvador.
Narrative Update • Sep 04

Global Expansion And Next-Generation Respiratory Care Will Transform Markets

With minimal changes in both the discount rate and future P/E, Beyond Air’s consensus analyst price target remained effectively unchanged at $11.20. What's in the News Expanded global LungFit PH distribution network to 34 countries, including new agreements in Japan (with AMCO), South Korea, Costa Rica, Guatemala, and El Salvador.
User avatar
New Narrative • Apr 14

The Next-Generation LungFit PH System Will Open New Markets

International revenue could significantly impact growth due to CE Mark approval and distribution partnerships, especially in the EU.

Earnings and Revenue Growth Forecasts

NasdaqCM:XAIR - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
3/31/202941-13N/AN/A1
3/31/202821-24N/AN/A1
12/31/20268-31N/AN/A1
3/31/20268-33-19-18N/A
12/31/20257-31-22-20N/A
9/30/20256-37-26-24N/A
6/30/20255-42-36-33N/A
3/31/20254-47-44-38N/A
12/31/20243-52-48-42N/A
9/30/20242-55-55-48N/A
6/30/20242-58-57-49N/A
3/31/20241-60-62-56N/A
12/31/20231-67-60-54N/A
9/30/20230-63-54-48N/A
6/30/20230-59-48-43N/A
3/31/2023N/A-56-37-33N/A
12/31/2022N/A-56-35-32N/A
9/30/2022N/A-51-32-30N/A
6/30/2022N/A-47-28-26N/A
3/31/2022N/A-43-25-23N/A
12/31/20210-28-22-21N/A
9/30/20210-26-21-20N/A
6/30/20211-23-19-18N/A
3/31/20211-23-21-20N/A
12/31/20201-23-20-19N/A
9/30/20201-22-19-18N/A
6/30/20201-21-18-18N/A
3/31/20201-20-15-15N/A
12/31/20199-15N/A-3N/A
9/30/20199-13N/A0N/A
6/30/20198-11N/A1N/A
3/31/20198-7N/A1N/A
12/31/2018N/A-5N/A-7N/A
9/30/2018N/A-5N/A-8N/A
6/30/2018N/A-10N/A-7N/A
3/31/2018N/A-11N/A-7N/A
12/31/2017N/A-18N/A-7N/A
9/30/2017N/A-17N/A-6N/A
6/30/2017N/A-11N/A-4N/A
3/31/2017N/A-9N/A-3N/A
12/31/2016N/A-4N/A-1N/A
9/30/2016N/A-3N/A-1N/A
6/30/2016N/A-4N/A-1N/A
3/31/2016N/A-4N/A-1N/A
12/31/2015N/A-4N/A-2N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: XAIR is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: XAIR is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: XAIR is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: XAIR's revenue (57.8% per year) is forecast to grow faster than the US market (12.7% per year).

High Growth Revenue: XAIR's revenue (57.8% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if XAIR's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/06 21:44
End of Day Share Price 2026/07/06 00:00
Earnings2026/03/31
Annual Earnings2026/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Beyond Air, Inc. is covered by 7 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Marie ThibaultBTIG
Michael GormanBTIG
Jason KolbertD. Boral Capital LLC.